SPRY
ARS Pharmaceuticals, Inc. (SPRY) Economic Moat Analysis (2026)
Overall Score
Scale Market Position
SPRY remains a sub-$1B market-cap company with limited scale, which constrains moat durability and bargaining power.
Revenue per share is only 0.9969, indicating a small operating base relative to valuation.
Pricing Power Margins
Gross margin is strong at 77.1%, but operating margin (-204.5%) and net margin (-200.0%) remain deeply negative, showing weak monetization.
High SG&A at 263.9% of revenue and R&D at 14.7% of revenue continue to pressure profitability.
Switching Costs Customer Stickiness
No fresh evidence indicates meaningful switching costs or entrenched customer lock-in.
The business still appears early-stage, with profitability and cash generation not yet demonstrating durable retention advantages.
Intangible Assets Regulatory Barriers
There is no fresh news of approvals, patents, or exclusivity events that would strengthen intangible barriers this month.
Intangibles remain modest at 4.9% of total assets, suggesting limited moat support from IP or regulatory protection.
Cost Advantage Efficiency
Operating efficiency remains poor, with return on invested capital at -85.0% and return on equity at -153.6%.
Cash conversion is still negative, and free cash flow yield is -29.3%, indicating no cost advantage yet.
Sources
- Company filings (10-K, 10-Q, investor presentations)
- Financial and market data providers
- Public news and industry information
🔒 Go Beyond This Framework
This is one of 10 institutional-grade frameworks Invetso runs on ARS Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

